Under the agreement, Catalent will produce JOTROL softgel capsules for Jupiter's upcoming Phase 2a clinical trial in Parkinson's disease. JOTROL is a resveratrol-based therapeutic designed to ...
According to a report by Nikkei, Tongfu Microelectronics is rumored to have commenced trial production of high bandwidth memory (HBM2). This development follows fellow Chinese manufacturer ...
Jupiter, Florida, Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, ...
This trial is a milestone for our Company ... The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform.